BPR1K871 DBPR114,98.45%
产品编号:Bellancom-100865| CAS NO:2443767-35-7| 分子式:C25H28ClN7O2S| 分子量:526.05
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
BPR1K871 DBPR114
| 产品介绍 | BPR1K871 (DBPR114) 是一种高效选择性的 FLT3/AURKA 双重抑制剂,对 FLT3 和 AURKA 作用的 IC50 值分别为 19 nM 和 22 nM。BPR1K871 可用于癌症的研究。 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy. | ||||||||||||||||
| 体外研究 |
BPR1K871 shows potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells with an EC50 of ~ 5 nM. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 |
BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 体内研究 |
BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| 溶解性数据 |
In Vitro:
DMSO : 125 mg/mL (237.62 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 |
| ||||||||||||||||
| 参考文献 |

浙公网安备 33010802013016号